Ekaterina Vorozheikina

Overview of Adverse Events Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Ekaterina Vorozheikina, Magdalena Ruiz, Leticia Solari, Dmitry Ostasevich & Luis Mendoza · International Blood Research & Reviews · 2021

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a novel immunotherapy that has shown remarkable success in the treatment of adult relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma, adult R/R mantle cell lymphoma, and R/R acute paediatric lymphoblastic leukaem...

Open access Research Article 10.9734/ibrr/2021/v12i430157

Importance of Glomerular Filtration Rate Determination and its Role in Drug-Dose Adjustments with Special Reference to Oncology

Brian Churchill, Ekaterina Vorozheikina, Anastasiya Vyshenskaya, Cecilia Sison & Luis Mendoza · Journal of Cancer and Tumor International · 2025

Glomerular filtration Rate (GFR) measured in steady state is the best marker of kidney function. Glomerular filtration rate can be determined using exogenous markers like inulin, iothalamate, or iohexol (mGFR), or estimated using endogenous markers like creatinine and cystatin C...

Open access Research Article 10.9734/jcti/2025/v15i1279

Chimeric Antigen Receptor-T Cell (CAR-T Cell) Therapy in Advanced Renal Cell Carcinoma

Brian Mark Churchill, Pallavi Patri, Jula K. Inrig, Anju Gopan, Ekaterina Vorozheikina, Luis Mendoza, Lara Kristina Donato & Ruma Pal Ghosh · International Research Journal of Oncology · 2021

With introduction of immunotherapy, the treatment of advanced renal cell carcinoma has undergone a substantial change. Immunotherapeutic agents including nivolumab, ipilimumab, pembrolizumab, have been introduced and approved for therapy of this life-threatening malignancy. Chime...

Open access Research Article